

Saverio Cinieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5055155/publications.pdf>

Version: 2024-02-01

101
papers

3,690
citations

159573

30
h-index

138468

58
g-index

102
all docs

102
docs citations

102
times ranked

5601
citing authors

#	ARTICLE	IF	CITATIONS
1	Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. <i>Journal of the American College of Cardiology</i> , 2000, 36, 517-522.	2.8	463
2	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327
3	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3002-3011.	1.6	229
4	Breast carcinoma in elderly women. <i>Cancer</i> , 2004, 101, 1302-1310.	4.1	176
5	Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1999, 106, 504-509.	2.5	151
6	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 561-568.	10.7	141
7	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1281-1287.	1.6	126
8	Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 961-967.	1.4	91
9	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	10.7	91
10	Assessing Tumor Angiogenesis. <i>Cancer Research</i> , 2004, 64, 4373-4377.	0.9	83
11	Weekly epirubicin in the treatment of gestational breast cancer (GBC). <i>Breast Cancer Research and Treatment</i> , 2009, 115, 591-594.	2.5	68
12	Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95. <i>Journal of Clinical Oncology</i> , 2006, 24, 370-378.	1.6	67
13	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	2.5	66
14	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3347-3353.	1.6	66
15	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	8.6	65
16	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	2.8	60
17	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
18	Targeting triple negative breast cancer with histone deacetylase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1199-1206.	4.1	58

#	ARTICLE	IF	CITATIONS
19	Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e74402.	2.5	56
20	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo) Tj ETQq0 0 0,rgBT /Overlock 10 Tf 262-273.	2.5	54
21	Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 243-251.	4.4	51
22	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study. <i>Lung Cancer</i> , 2013, 81, 77-83.	2.0	51
23	Role of gemcitabine in metastatic breast cancer patients: A short review. <i>Breast</i> , 2008, 17, 220-226.	2.2	47
24	Nutritional support for cancer patients: still a neglected right?. <i>Supportive Care in Cancer</i> , 2017, 25, 3001-3004.	2.2	42
25	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-“Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2585-2592.	1.6	42
26	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186.	2.8	39
27	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , 2010, 36, S87-S94.	7.7	36
28	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	2.0	35
29	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33
30	Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. <i>Breast</i> , 2016, 30, 151-155.	2.2	32
31	MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. <i>Lung Cancer</i> , 2012, 76, 373-379.	2.0	31
32	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 155-162.	3.1	27
33	Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the SocietÀ Italiana di Nefrologia (SIN). <i>ESMO Open</i> , 2017, 2, e000167.	4.5	27
34	Fatherhood during imatinib. <i>Acta OncolÃ³gica</i> , 2011, 50, 734-735.	1.8	26
35	<i>Toxoplasma gondii</i> infection in patients with hematological malignancies. <i>Annals of Hematology</i> , 2004, 83, 592-595.	1.8	25
36	Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 166-170.	2.6	25

#	ARTICLE	IF	CITATIONS
37	Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 291-301.	4.4	24
38	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1830-1844.	1.1	23
39	BMI variation increases recurrence risk in women with early-stage breast cancer. <i>Future Oncology</i> , 2014, 10, 2459-2468.	2.4	23
40	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	3.7	23
41	Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. <i>European Journal of Haematology</i> , 2004, 72, 264-267.	2.2	20
42	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141.	2.8	20
43	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReND trial. <i>Breast Cancer Research</i> , 2019, 21, 71.	5.0	19
44	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 535-540.	1.4	19
45	Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6039-6046.	7.0	18
46	Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPIO study. <i>Future Oncology</i> , 2019, 15, 33-44.	2.4	18
47	First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. <i>Lung Cancer</i> , 2010, 69, 218-224.	2.0	17
48	Italian Multicenter Phase III Randomized Study of Cisplatin-Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial. <i>Clinical Lung Cancer</i> , 2015, 16, 67-70.	2.6	17
49	Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review. <i>Tumori</i> , 2011, 97, 690-692.	1.1	16
50	Electrophysiological and Neuropsychological Functions in Patients Treated with Interferon- β . <i>Journal of Interferon Research</i> , 1990, 10, 613-619.	1.2	15
51	Adjuvant Therapy for Very Young Women with Breast Cancer: Response According to Biologic and Endocrine Features. <i>Clinical Breast Cancer</i> , 2004, 5, 125-130.	2.4	15
52	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 57-68.	4.4	15
53	Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group) Tj ETQq1 1 0.784314 rgb / Over	1.1	15
54	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	1.1	15

#	ARTICLE	IF	CITATIONS
55	Rituximab in Lymphocyte-Predominant Hodgkin Disease. <i>Oncology</i> , 2009, 76, 26-29.	1.9	14
56	Genistein: The future of prevention and treatment of breast cancer?. <i>Cancer Biology and Therapy</i> , 2011, 11, 918-920.	3.4	13
57	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S111-S117.	3.4	13
58	Efficacy and safety of eribulin in taxane-refractory patients in the "real world"™. <i>Future Oncology</i> , 2017, 13, 971-978.	2.4	13
59	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	2.6	12
60	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	2.0	12
61	Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies. <i>Breast</i> , 2010, 19, 214-218.	2.2	11
62	Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life"Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non"Small-Cell Lung Cancer (ERACLE). <i>Clinical Lung Cancer</i> , 2011, 12, 402-406.	2.6	11
63	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.4	11
64	Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for"HER2-Negative Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 91-99.e1.	2.4	11
65	Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs. <i>Medical Oncology</i> , 2019, 36, 80.	2.5	11
66	Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). <i>Breast</i> , 2019, 45, 7-14.	2.2	11
67	Biochemical and immunological responses of hairy cell leukemia patients to interferon"2. <i>Cancer Immunology, Immunotherapy</i> , 1991, 34, 115-122.	4.2	10
68	Combined modality treatments in pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S71-S81.	3.4	10
69	Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?. <i>Medical Oncology</i> , 2013, 30, 578.	2.5	9
70	A clinical evaluation of treatments that target cell cycle machinery in breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2305-2315.	1.8	9
71	Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S83-S89.	3.4	8
72	Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy. <i>Future Oncology</i> , 2017, 13, 233-248.	2.4	8

#	ARTICLE	IF	CITATIONS
73	An update on first line therapies for metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 243-252.	1.8	8
74	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. European Journal of Cancer, 2021, 154, 21-29.	2.8	8
75	Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). Tumori, 2011, 97, 442-448.	1.1	7
76	Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. Biology of Blood and Marrow Transplantation, 2014, 20, 501-506.	2.0	7
77	Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). Breast, 2020, 53, 18-22.	2.2	7
78	Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon γ in hairy-cell leukemia patients. Cancer Immunology, Immunotherapy, 1994, 38, 323-331.	4.2	6
79	Panitumumab after Progression on Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients: a Single Institution Experience. Tumori, 2015, 101, 524-528.	1.1	6
80	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. BMC Cancer, 2018, 18, 932.	2.6	6
81	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. Journal of Geriatric Oncology, 2019, 10, 591-597.	1.0	6
82	Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. Journal of Clinical Oncology, 2005, 23, 232-233.	1.6	5
83	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. Lung Cancer, 2019, 133, 62-68.	2.0	5
84	Modulation of NK activity by thymic hormones: in vitro effects of thymostimulin. Medical Oncology and Tumor Pharmacotherapy, 1989, 6, 45-52.	1.1	4
85	Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients. Journal of Chemotherapy, 2013, 25, 369-375.	1.5	3
86	Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. Future Oncology, 2014, 10, 725-733.	2.4	3
87	Pharmacotherapeutic options for patients with refractory breast cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 851-861.	1.8	3
88	A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale. Future Oncology, 2022, 18, 771-779.	2.4	3
89	First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Clinical Drug Investigation, 2012, 32, 755-760.	2.2	2
90	Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). Seminars in Oncology, 2018, 45, 259-263.	2.2	2

#	ARTICLE	IF	CITATIONS
91	Second-line erlotinib for non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2012, 13, e141-e142.	10.7	1
92	Response of Extensive Breast Cancer Skin Metastases to Rechallenge with Trastuzumab Together with Low-Dose Chemotherapy and Insulin. <i>Tumori</i> , 2016, 102, S26-S28.	1.1	1
93	CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?. <i>Future Medicinal Chemistry</i> , 2019, 11, 1237-1239.	2.3	1
94	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. <i>Tumori</i> , 2014, 100, e309-13.	1.1	1
95	REPLY TO GUNSILIUS ET AL. <i>British Journal of Haematology</i> , 2000, 108, 662-663.	2.5	0
96	Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 473-475.	3.4	0
97	Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey. <i>Future Oncology</i> , 2014, 10, 69-78.	2.4	0
98	Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer?. <i>Future Oncology</i> , 2017, 13, 1361-1364.	2.4	0
99	Tumor Control Achieved Despite Loss of Chimaerism in Renal Cell Carcinoma (RCC) Following Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Case Report.. <i>Blood</i> , 2005, 106, 5401-5401.	1.4	0
100	Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , 2013, 99, 35-8.	1.1	0
101	Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis. <i>Tumori</i> , 2014, 100, 426-31.	1.1	0